Adverum Biotechnologies, Inc. (ADVM)
Largest Insider Buys in Sector
ADVM Stock Price History Chart
ADVM Stock Performance
About Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly …
Insider Activity of Adverum Biotechnologies, Inc.
Over the last 12 months, insiders at Adverum Biotechnologies, Inc. have bought $2.71M and sold $0 worth of Adverum Biotechnologies, Inc. stock.
On average, over the past 5 years, insiders at Adverum Biotechnologies, Inc. have bought $802,088 and sold $1.39M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Leonard Braden Michael (10 percent owner) — $19.19M. Lupher, Jr. Mark L. (director) — $175,500. Scopa James Paul (director) — $135,000.
The last purchase of 85,800 shares for transaction amount of $613,470 was made by Leonard Braden Michael (10 percent owner) on 2024‑07‑30.
List of Insider Buy and Sell Transactions, Adverum Biotechnologies, Inc.
| 2024-07-30 | 10 percent owner | 85,800 0.3983% | $7.15 | $613,470 | +5.87% | |||
| 2024-07-18 | 10 percent owner | 80,718 0.3739% | $9.11 | $735,737 | -25.63% | |||
| 2024-07-17 | 10 percent owner | 135,546 0.5761% | $7.75 | $1.05M | -19.70% | |||
| 2024-02-07 | director | 130,000 0.1654% | $1.35 | $175,500 | -72.14% | |||
| 2024-02-07 | director | 100,000 0.1273% | $1.35 | $135,000 | -72.14% | |||
| 2023-09-15 | Sale | Chief Development Officer | 6,201 0.006% | $1.52 | $9,429 | -41.47% | ||
| 2023-06-07 | Chief Financial Officer | 100,000 0.098% | $1.45 | $145,490 | -18.95% | |||
| 2023-03-15 | Sale | CEO, President and Director | 41,239 0.0397% | $0.78 | $32,232 | +25.15% | ||
| 2023-03-15 | Sale | Chief Operating Officer | 13,360 0.0128% | $0.78 | $10,442 | +25.15% | ||
| 2023-03-15 | Sale | Chief Scientific Officer | 7,299 0.007% | $0.78 | $5,705 | +25.15% | ||
| 2022-05-23 | Chief Development Officer | 20,000 0.0205% | $0.84 | $16,800 | +0.48% | |||
| 2022-05-17 | Chief Medical Officer | 10,000 0.01% | $0.82 | $8,228 | +0.60% | |||
| 2022-05-16 | 30,000 0.0319% | $0.85 | $25,578 | +2.84% | ||||
| 2022-05-13 | Chief Financial Officer | 10,000 0.0104% | $0.86 | $8,585 | +0.06% | |||
| 2022-04-20 | CEO, President and Director | 25,000 0.0246% | $1.11 | $27,800 | -23.16% | |||
| 2022-04-19 | See Remarks section | 21,750 0.0224% | $1.14 | $24,795 | -21.79% | |||
| 2021-12-09 | CEO, President and Director | 14,323 0.0147% | $1.85 | $26,498 | -35.87% | |||
| 2021-12-08 | CEO, President and Director | 10,677 0.0104% | $1.79 | $19,112 | -36.90% | |||
| 2021-12-08 | See Remarks section | 25,000 0.026% | $1.91 | $47,750 | -36.90% | |||
| 2021-11-15 | Sale | director | 50,000 0.0512% | $2.18 | $109,000 | -41.71% |
Insider Historical Profitability
| Leonard Braden Michael | 10 percent owner | 2268064 10.9028% | $4.74 | 3 | 0 | |
| Lupher, Jr. Mark L. | director | 130000 0.6249% | $4.74 | 1 | 0 | |
| Scopa James Paul | director | 100000 0.4807% | $4.74 | 3 | 1 | +22.77% |
| Venrock Associates VI, L.P. | 10 percent owner | 2365471 11.3711% | $4.74 | 1 | 0 | |
| Venrock Healthcare Capital Partners II, L.P. | 10 percent owner | 2365471 11.3711% | $4.74 | 1 | 0 |
Institutional Investor Ownership
| Tcg Crossover Management Llc | $28.4M | 9.68 | 2.01M | New | +$28.4M | 0.05 | |
| Vr Adviser Llc | $22.01M | 7.5 | 1.56M | -69.76% | -$50.78M | 1.07 | |
| Vivo Capital | $21.21M | 7.23 | 1.5M | New | +$21.21M | 1.85 | |
| Logos Global Management Lp | $21.21M | 7.23 | 1.5M | New | +$21.21M | 2.29 | |
| Frazier Life Sciences Management L P | $15.12M | 5.15 | 1.07M | New | +$15.12M | 0.68 |